Equillium Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 14

Employees

  • Stock Symbol
  • EQ

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.29
  • (As of Friday Closing)

Equillium General Information

Description

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Contact Information

Website
www.equilliumbio.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2223 Avenida De La Playa
  • Suite 105
  • La Jolla, CA 92037
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences
Corporate Office
  • 2223 Avenida De La Playa
  • Suite 105
  • La Jolla, CA 92037
  • United States
+1 (858)

Equillium Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Equillium Stock Performance

As of 13-Nov-2026, Equillium’s stock price is $1.29. Its current market cap is $106M with 82.3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.29 $1.32 $0.76 - $3.54 $106M 82.3M 526K -$0.18

Equillium Financials Summary

As of 30-Sep-2026, Equillium has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 46,458 62,010 1,129 (19,989)
Revenue 0 0 41,095 36,084
EBITDA (19,876) (23,115) (8,950) (14,472)
Net Income (18,362) (22,398) (8,067) (13,335)
Total Assets 55,811 31,887 25,604 50,530
Total Debt 765 719 384 824
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Equillium Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Equillium‘s full profile, request access.

Request a free trial

Equillium Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disord
Drug Discovery
La Jolla, CA
14 As of 2025

Melbourne, Australia
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Equillium Competitors (66)

One of Equillium’s 66 competitors is Mesoblast, a Corporation company based in Melbourne, Australia.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mesoblast Corporation Melbourne, Australia
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
Statera Biopharma Formerly VC-backed Fort Collins, CO
CSL Behring Corporation King Of Prussia, PA
You’re viewing 5 of 66 competitors. Get the full list »

Equillium Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 7

    Pending

  • Expiring in next 12 mo

Equillium Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2023552762-A Method of selectively targeting cd6high cells to reduce teff cell activity Pending 04-Dec-2020
EP-4255452-A1 Methods of selectively targeting cd6 high cells and decreasing activity of t eef cells Inactive 04-Dec-2020
EP-4255452-A4 Methods of selectively targeting cd6 high cells and decreasing activity of t eef cells Inactive 04-Dec-2020
AU-2021392748-A1 Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells Inactive 04-Dec-2020
AU-2021392748-A9 Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells Inactive 04-Dec-2020
To view Equillium’s complete patent history, request access »

Equillium Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Equillium Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Equillium‘s full profile, request access.

Request a free trial

Equillium Acquisitions (1)

Equillium’s most recent deal was a Merger/Acquisition with Bioniz Therapeutics for . The deal was made on 14-Feb-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Bioniz Therapeutics 14-Feb-2022 Merger/Acquisition Drug Delivery
To view Equillium’s complete acquisitions history, request access »

Equillium ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

34.9 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Equillium’s complete esg history, request access »

Equillium FAQs

  • When was Equillium founded?

    Equillium was founded in 2017.

  • Where is Equillium headquartered?

    Equillium is headquartered in La Jolla, CA.

  • What is the size of Equillium?

    Equillium has 14 total employees.

  • What industry is Equillium in?

    Equillium’s primary industry is Drug Discovery.

  • Is Equillium a private or public company?

    Equillium is a Public company.

  • What is Equillium’s stock symbol?

    The ticker symbol for Equillium is EQ.

  • What is the current stock price of Equillium?

    As of 13-Nov-2026 the stock price of Equillium is $1.29.

  • What is the current market cap of Equillium?

    The current market capitalization of Equillium is $106M.

  • Who are Equillium’s competitors?

    Mesoblast, Inovio Pharmaceuticals, Marengo Therapeutics, Statera Biopharma, and CSL Behring are some of the 66 competitors of Equillium.

  • What is Equillium’s annual earnings per share (EPS)?

    Equillium’s EPS for 12 months was -$0.18.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process